D

DFTX

DFTX

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
DFTX Live QuoteReal-time
$29.48
$6.01(-16.93%)1M
Day Range$28.23 – $29.98
Open$29.44
Previous Close$29.12
Volume3.07M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$3.99B
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-2.92
Price to Book4.2
Dividend Yield0.65%
Beta (Volatility)2.21
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $29.48 (48%)
Low: $10.46High: $49.70
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$72.83-51.4% upside

Insider Buys

0

$0

Insider Sales

5

$2.30M

Total Volume

$2.30M

8 transactions

Net Activity

$2.30M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
25CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
B
1

Barrow Robert

CEO

0 buys1 sells

$1.15M total

S
2

Sullivan Mark

GC

0 buys1 sells

$514K total

K
3

Karlin Daniel

Chief Medical Officer

0 buys1 sells

$397K total

R
4

Roberts Brandi

CFO

0 buys1 sells

$123K total

W
5

Wiley Matthew T.

Chief Commercial Officer

0 buys1 sells

$113K total

Trading History
DFTX insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 25, 2026

1 months ago

Roberts Brandi

CFO

CFO
Sell3.4K$36.57$123K

Sep 25, 2026

1 months ago

Barrow Robert

CEO

CEO
Sell31.6K$36.57$1.15M

Sep 25, 2026

1 months ago

Wiley Matthew T.

Chief Commercial Officer

C-Level
Sell3.1K$36.57$113K

Sep 25, 2026

1 months ago

Sullivan Mark

GC

General Counsel
Sell14.1K$36.57$514K

Sep 25, 2026

1 months ago

Karlin Daniel

Chief Medical Officer

C-Level
Sell10.9K$36.57$397K

Sep 3, 2026

2 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell1.49M$-19023.00$0

Jun 25, 2026

4 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell320.6K$-13008.00$0

Mar 25, 2026

8 months ago

Multiple Insiders

S - Sale Insiders

Insider
Sell413.3K$-8018.00$0
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
DFTX Buy Conviction0%
Industry Rank#0 of 569
Volume Contribution0.0%
Total Industry Activity$16.53B

DFTX has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for DFTX

Over the last 90 days, corporate insiders at DFTX (DFTX) engaged in a total of 8 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 5 were sales. The total volume of insider trading reached $2.30M.

The net insider activity for DFTX shows a net selling bias of $2.30M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Barrow Robert (CEO), who traded 31.6K shares valued at $1.15M on Sep 25, 2026.

Live Market News & Developments
Aggregated real-time headlines for DFTX (DFTX)
6 updates

Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value

Yahoo Finance32d ago

Definium Therapeutics: Outstanding Phase III Data De-Risks Pipeline, But Patience Required Ahead Of 2027

Seeking Alpha38d ago

Definium Therapeutics (DFTX) Could Be 52% Undervalued Following Third Quarter Earnings

Simply Wall St7h ago

Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress

Moomoo77d ago

DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data

TradingView101d ago

Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results

Yahoo Finance66d ago

FAQs About DFTX Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for DFTX.

Based on SEC Form 4 disclosures, the Insider Confidence Score for DFTX is currently 25/100, which reflects a moderate distribution bias. This calculation accounts for a total of 0 purchases and 5 sales by company executives over the last 90 days.

The CEO Conviction Index for DFTX is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.